---
title: "EASTON BIOPHARMACEUTICALS released its performance for the first half of the year, with a net profit attributable to the parent company of 137 million yuan, a decrease of 6.77%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253465987.md"
description: "EASTON BIOPHARMACEUTICALS released its semi-annual report for 2025, with operating revenue of 654 million yuan, a year-on-year decrease of 2.25%; net profit attributable to the parent company was 137 million yuan, a year-on-year decline of 6.77%. The net profit after deducting non-recurring gains and losses was 104 million yuan, a year-on-year decrease of 8.68%. The basic earnings per share were 0.77 yuan. The decline in performance was mainly due to the impact of the national centralized procurement on the sales of chemical preparations and the increase in equity incentive expenses"
datetime: "2025-08-18T12:20:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253465987.md)
  - [en](https://longbridge.com/en/news/253465987.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253465987.md)
generator: "portal-rs"
---

# EASTON BIOPHARMACEUTICALS released its performance for the first half of the year, with a net profit attributable to the parent company of 137 million yuan, a decrease of 6.77%

According to the Zhitong Finance APP, EASTON BIOPHARMACEUTICALS (688513.SH) released its semi-annual report for 2025, showing an operating income of 654 million yuan, a year-on-year decrease of 2.25%. The net profit attributable to shareholders of the listed company was 137 million yuan, a year-on-year decrease of 6.77%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 104 million yuan, a year-on-year decrease of 8.68%. The basic earnings per share were 0.77 yuan. The decline in operating income and net profit compared to the same period last year was mainly due to the implementation of the tenth batch of national centralized procurement, which led to a decrease in sales revenue from chemical preparations, and an increase in equity incentive expenses during the reporting period compared to the previous year

### Related Stocks

- [688513.CN](https://longbridge.com/en/quote/688513.CN.md)

## Related News & Research

- [Pandora board member Lars Sandahl Sørensen buys shares for DKK 164,308](https://longbridge.com/en/news/296865688.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [BMS Holdings Q4 FY2026 PAT Rises 106.5% QoQ to RM5.04 Million](https://longbridge.com/en/news/296892849.md)
- [Dino Polska S.A. (WSE:DNP) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year](https://longbridge.com/en/news/296763667.md)
- [11:55 ETTaco Lubbock Earns ASME and National Board Certifications, Expanding Manufacturing Capabilities](https://longbridge.com/en/news/296937170.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**